NASDAQ:SCLX Scilex (SCLX) Stock Price, News & Analysis $16.82 +1.04 (+6.59%) Closing price 04:00 PM EasternExtended Trading$17.34 +0.52 (+3.06%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Scilex Stock (NASDAQ:SCLX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Scilex alerts:Sign Up Key Stats Today's Range$15.40▼$17.6950-Day Range$12.94▼$30.0052-Week Range$3.60▼$39.90Volume304,252 shsAverage Volume294,576 shsMarket Capitalization$117.07 millionP/E RatioN/ADividend YieldN/APrice Target$455.00Consensus RatingHold Company Overview Scilex Holdings, Inc. (NASDAQ: SCLX) is a specialty pharmaceutical company focused on non-opioid treatments for chronic pain. The firm’s principal commercial product, ZTlido®, is a lidocaine topical system approved by the U.S. Food and Drug Administration for the management of post-herpetic neuralgia and certain peripheral neuropathic pain conditions. By leveraging a proprietary drug delivery platform, Scilex aims to improve patient comfort and safety compared to traditional oral analgesics. In addition to marketing ZTlido® in the United States, Scilex is advancing other pain management assets through clinical development and regulatory pathways. The company’s pipeline includes additional topical and localized therapies designed to address a range of acute and chronic pain indications without the abuse potential associated with opioid medications. Scilex pursues both in-house research and selective licensing partnerships to broaden its offering. Headquartered in San Diego, California, Scilex operates primarily in the U.S. market, where it works with healthcare providers, specialty pharmacies and distributors to ensure patient access to its products. The company’s management team brings experience in pharmaceutical development, regulatory affairs and commercial operations, supporting Scilex’s strategy of targeted growth within the pain therapeutics space.AI Generated. May Contain Errors. Read More Scilex Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreSCLX MarketRank™: Scilex scored higher than 48% of companies evaluated by MarketBeat, and ranked 594th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingHold Consensus RatingScilex has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialScilex has a consensus price target of $455.00, representing about 2,605.1% upside from its current price of $16.82.Amount of Analyst CoverageScilex has only been the subject of 1 research reports in the past 90 days.Read more about Scilex's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Scilex are expected to grow in the coming year, from ($0.57) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Scilex is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Scilex is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Scilex's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.32% of the float of Scilex has been sold short.Short Interest Ratio / Days to CoverScilex has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Scilex has recently increased by 5.72%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldScilex does not currently pay a dividend.Dividend GrowthScilex does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.32% of the float of Scilex has been sold short.Short Interest Ratio / Days to CoverScilex has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Scilex has recently increased by 5.72%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News Sentiment0.91 News SentimentScilex has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Scilex this week, compared to 2 articles on an average week.Search InterestOnly 16 people have searched for SCLX on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows19 people have added Scilex to their MarketBeat watchlist in the last 30 days. This is an increase of 280% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Scilex insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.94% of the stock of Scilex is held by insiders.Percentage Held by Institutions69.67% of the stock of Scilex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Scilex's insider trading history. Receive SCLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scilex and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SCLX Stock News HeadlinesDatavault AI: The New AI Contender Backed by Big Funding (SCLX)Datavault AI's recent nine-figure investment and a partnership with IBM signal a fundamental inflection point for this emerging AI growth company.October 1, 2025 | marketbeat.comScilex Holding Company Enters Warrant Exercise AgreementOctober 1, 2025 | tipranks.comWall Street legend: “Sell this A.I. stock now”Whats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.October 6 at 2:00 AM | Chaikin Analytics (Ad)Scilex Holding Company Completes Repurchase of 3.13 Million Warrants from Oramed Pharmaceuticals for $13 MillionOctober 1, 2025 | quiverquant.comQScilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant RepurchaseOctober 1, 2025 | globenewswire.comDatavault AI: Fresh Capital, Blue-Chip Partnership Back A Speculative BuySeptember 30, 2025 | seekingalpha.comScilex Holding Company Updates Board After Business MergerSeptember 26, 2025 | tipranks.comDatavault AI Announces Closing of Initial Tranche Investment from Scilex Holding CompanySeptember 26, 2025 | businesswire.comSee More Headlines SCLX Stock Analysis - Frequently Asked Questions How have SCLX shares performed this year? Scilex's stock was trading at $14.9240 at the start of the year. Since then, SCLX shares have increased by 12.7% and is now trading at $16.82. How were Scilex's earnings last quarter? Scilex Holding Company (NASDAQ:SCLX) issued its earnings results on Wednesday, August, 13th. The company reported ($7.42) EPS for the quarter, missing analysts' consensus estimates of ($4.55) by $2.87. The firm earned $9.90 million during the quarter, compared to the consensus estimate of $26.25 million. When did Scilex's stock split? Scilex shares reverse split on the morning of Tuesday, April 15th 2025.The 1-35 reverse split was announced on Friday, April 11th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 14th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Scilex? Shares of SCLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Scilex own? Based on aggregate information from My MarketBeat watchlists, some other companies that Scilex investors own include Rigetti Computing (RGTI), Pfizer (PFE), BioNTech (BNTX), Hertz Global (HTZ), BlackBerry (BB). Company Calendar Last Earnings8/13/2025Today10/06/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SCLX CIK1820190 Webwww.scilexholding.com Phone650-516-4310FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Price Target for Scilex$455.00 High Price Target$630.00 Low Price Target$245.00 Potential Upside/Downside+2,605.1%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($29.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$72.81 million Net Margins-179.12% Pretax Margin-183.01% Return on EquityN/A Return on Assets-109.95% Debt Debt-to-Equity RatioN/A Current Ratio0.11 Quick Ratio0.10 Sales & Book Value Annual Sales$56.59 million Price / Sales2.07 Cash FlowN/A Price / Cash FlowN/A Book Value($27.68) per share Price / Book-0.61Miscellaneous Outstanding Shares6,960,000Free Float6,404,000Market Cap$117.07 million OptionableNo Data Beta1.36 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:SCLX) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIs This Warren’s Buffett’s #1 AI Investment?Did you know that Warren Buffett is investing in what Jeff Brown believes will be the next generation of artif...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scilex Holding Company Please log in to your account or sign up in order to add this asset to your watchlist. Share Scilex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.